Free Trial

HCW Biologics (HCWB) Competitors

HCW Biologics logo
$8.70 -0.48 (-5.23%)
Closing price 04:00 PM Eastern
Extended Trading
$8.48 -0.23 (-2.59%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCWB vs. PLUR, ONCY, ELYM, RVPH, ACRV, ALGS, ESLA, ATHE, FBLG, and OSTX

Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Pluri (PLUR), Oncolytics Biotech (ONCY), Eliem Therapeutics (ELYM), Reviva Pharmaceuticals (RVPH), Acrivon Therapeutics (ACRV), Aligos Therapeutics (ALGS), Estrella Immunopharma (ESLA), Alterity Therapeutics (ATHE), FibroBiologics (FBLG), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry.

HCW Biologics vs.

Pluri (NASDAQ:PLUR) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.

16.6% of Pluri shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 10.2% of Pluri shares are held by insiders. Comparatively, 49.9% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HCW Biologics has a net margin of -1,067.82% compared to Pluri's net margin of -3,551.49%. HCW Biologics' return on equity of -2,516.84% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-3,551.49% -2,778.13% -83.61%
HCW Biologics -1,067.82%-2,516.84%-132.95%

HCW Biologics received 6 more outperform votes than Pluri when rated by MarketBeat users.

CompanyUnderperformOutperform
PluriN/AN/A
HCW BiologicsOutperform Votes
6
100.00%
Underperform Votes
No Votes

Pluri has higher earnings, but lower revenue than HCW Biologics. Pluri is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$1.03M34.88-$20.89M-$5.53-0.83
HCW Biologics$1.45M8.66-$24.99M-$23.25-0.37

In the previous week, HCW Biologics had 6 more articles in the media than Pluri. MarketBeat recorded 9 mentions for HCW Biologics and 3 mentions for Pluri. Pluri's average media sentiment score of 0.42 beat HCW Biologics' score of 0.42 indicating that Pluri is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pluri
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HCW Biologics
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pluri has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Summary

Pluri and HCW Biologics tied by winning 7 of the 14 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCWB vs. The Competition

MetricHCW BiologicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.52M$6.52B$5.37B$8.38B
Dividend YieldN/A2.65%5.22%4.11%
P/E Ratio-8.708.9226.8419.71
Price / Sales8.66253.80392.34117.39
Price / CashN/A65.8538.2534.62
Price / Book23.516.466.794.50
Net Income-$24.99M$143.98M$3.23B$248.18M
7 Day Performance-1.25%3.04%4.07%1.14%
1 Month Performance11.97%7.44%12.52%15.20%
1 Year Performance-80.41%-2.46%16.83%6.56%

HCW Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCWB
HCW Biologics
1.5498 of 5 stars
$8.70
-5.2%
N/A-79.3%$12.52M$1.45M-8.7040Earnings Report
PLUR
Pluri
0.4066 of 5 stars
$4.95
-5.0%
N/A-19.5%$38.47M$678,000.00-0.88150
ONCY
Oncolytics Biotech
1.7174 of 5 stars
$0.44
-4.9%
$4.33
+874.7%
-61.6%$38.42MN/A-1.6530Earnings Report
Analyst Forecast
Gap Down
ELYM
Eliem Therapeutics
N/A$1.29
+7.5%
N/A-84.5%$38.38MN/A-2.439
RVPH
Reviva Pharmaceuticals
3.4331 of 5 stars
$0.89
+8.5%
$10.00
+1,023.6%
-32.5%$38.33MN/A-0.805News Coverage
Earnings Report
Analyst Forecast
ACRV
Acrivon Therapeutics
3.1897 of 5 stars
$1.18
+2.6%
$17.71
+1,401.2%
-85.4%$37.00MN/A-0.4458Analyst Revision
High Trading Volume
ALGS
Aligos Therapeutics
3.4341 of 5 stars
$5.89
+0.9%
$70.00
+1,088.5%
-63.9%$36.01M$3.27M-0.4490Gap Down
ESLA
Estrella Immunopharma
1.4964 of 5 stars
$0.99
+2.7%
$16.00
+1,524.4%
-6.7%$35.62MN/A-3.79N/AGap Up
ATHE
Alterity Therapeutics
1.9635 of 5 stars
$4.05
+1.5%
$12.00
+196.3%
+114.3%$35.38MN/A0.0010
FBLG
FibroBiologics
1.5731 of 5 stars
$0.91
-2.5%
$13.00
+1,327.2%
-91.7%$34.85MN/A-4.3410
OSTX
OS Therapies
2.0506 of 5 stars
$1.59
-3.0%
$18.00
+1,032.1%
N/A$34.45MN/A-1.85N/AGap Up

Related Companies and Tools


This page (NASDAQ:HCWB) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners